We tested the hypothesis that the albumin-docking protein gp60, which is lo
calized in caveolae, couples to the heterotrimeric GTP binding protein G(i)
, and thereby activates plasmalemmal vesicle formation and the directed mig
ration of vesicles in endothelial cells (ECs). We used the water-soluble st
yryl pyridinium dye N-(3-triethylaminopropyl)-4-(p-dibutylaminostyryl) pyri
dinium dibromide (FM 1-43) to quantify vesicle trafficking by confocal and
digital fluorescence microscopy. FM 1-43 and fluorescently labeled anti-gp6
0 antibody (Ab) were colocalized in endocytic vesicles within 5 min of gp60
activation. Vesicles migrated to the basolateral surface where they releas
ed FM 1-43, the fluid phase styryl probe. FM 1-43 fluorescence disappeared
from the basolateral EC surface without the loss of anti-gp60 Ab fluorescen
ce. Activation of cell-surface gp60 by cross-linking (using anti-gp60 Ab an
d secondary Ab) in EC grown on microporous filters increased transendotheli
al I-125-albumin permeability without altering liquid permeability (hydraul
ic conductivity), thus, indicating the dissociation of hydraulic conductivi
ty from the albumin permeability pathway. The findings that the sterol bind
ing agent, filipin, prevented gp60-activated vesicle formation and that cav
eolin-1 and gp60 were colocalized in vesicles suggest the caveolar origin o
f endocytic vesicles. Pertussis toxin pretreatment and expression of the do
minant negative construct encoding an 11-amino acid G(alpha i) carboxyl-ter
minal peptide inhibited endothelial I-125-albumin endocytosis and vesicle f
ormation induced by gp60 activation. Expression of dominant negative Src (d
n-Src) and overexpression of wild-type caveolin-1 also prevented gp60-activ
ated endocytosis. Caveolin-1 overexpression resulted in the sequestration o
f G(alpha i) with the caveolin-1, whereas dn-Src inhibited G(alpha i) bindi
ng to caveolin-1,Thus, vesicle formation induced by gp60 and migration of v
esicles to the basolateral membrane requires the interaction of gp60 with c
aveolin-1, followed by the activation of the downstream G(i)-coupled Src ki
nase signaling pathway.